Sunday 18 October 2026 Export ATOS’s income statement to Excel — free account

Atossa Therapeutics, Inc.

In the quarter to June 2026, EPS grew 9.48% and free cash flow fell 32.9%, each against the same quarter a year earlier.

2.91 0.26 +9.81%

Follow ATOS

Alert me

Market cap: $26.4M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: −15.64
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 26.44

Revenue 0.04

Net Income (37.71)

Free Cash Flow (35.77)

Net Debt (26.20)

Current Ratio 5.69

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 646.51

P/B ratio 0.97

Past 5Y EPS Growth —

This Y EPS Growth 7.26%

Next Y EPS Growth 25.71%

Next Y revenue growth —

Next 5Y EPS Growth 58.12%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 48.43%

10-year low 10-year high

P/B against its own 10 years 28.31%

10-year low 10-year high

EV/FCF against its own 10 years 1.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	89	71	41	26
Receivables	—	—	—	—
Inventory	—	—	—	3
Other	1	2	3	3
	92	74	46	31

	2023	2024	2025	Q'26
Payables	1	1	4	2
ST’ Debt	—	—	—	—
Other	3	3	3	2
	5	5	8	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(84.48%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	26.53%	7.69%	(30.65%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(10)	—	—	—
’25	(6)	(7)	(6)	(11)	(30)
’24	(5)	(5)	(5)	(7)	(21)
’23	(7)	(4)	(4)	(6)	(21)
’22	(5)	(6)	(5)	(5)	(21)
’21	(4)	(5)	(3)	(4)	(16)
’20	(3)	(2)	(3)	(3)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(10)	—	—	—
’25	(6)	(7)	(6)	(11)	(30)
’24	(5)	(5)	(5)	(7)	(21)
’23	(7)	(4)	(4)	(6)	(21)
’22	(5)	(6)	(5)	(5)	(21)
’21	(4)	(5)	(3)	(4)	(16)
’20	(3)	(2)	(3)	(3)	(12)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.11)	(0.95)	—	—	—
’25	(0.75)	(1.05)	(1.05)	(1.27)	(4.04)
’24	(0.75)	(0.75)	(0.90)	(0.75)	(3.00)
’23	(0.75)	(1.20)	(0.75)	(0.90)	(3.60)
’22	(0.60)	(0.75)	(0.90)	(0.90)	(3.15)
’21	(0.60)	(0.90)	(0.60)	(0.60)	(2.70)
’20	(4.80)	(6.45)	(5.10)	(13.34)	(29.53)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	234.00	39.60	12.00	14.85	11.40	13.20	7.50	8.25	11.55	8.25	Analyst estimates 2026–2028 Powerpack
	High	1,917.00	333.00	160.20	110.85	76.20	147.00	27.00	20.85	34.65	19.35
People
People	Employees	6	7	6	6	8	8	11	10	13	14
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(6)	(8)	(11)	(17)	(18)	(21)	(27)	(30)	(26)	(35)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(6)	(8)	(11)	(17)	(18)	(21)	(27)	(30)	(26)	(35)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(388.97)	(97.98)	(82.46)	(30.43)	(29.53)	(2.70)	(3.15)	(3.60)	(3.00)	(4.04)
	Cash flow	(327.72)	(101.45)	(32.32)	(16.11)	(15.34)	(2.11)	(2.46)	(2.49)	(2.51)	(3.46)
	Capex	(0.56)	0.00	(0.40)	(0.01)	(0.01)	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(328.28)	(101.45)	(32.72)	(16.12)	(15.35)	(2.11)	(2.46)	(2.49)	(2.51)	(3.46)
	Book value	188.85	106.75	31.75	23.22	36.02	17.71	13.97	10.82	8.52	4.57
	Shares, m	0	0	0	1	1	8	8	8	8	9
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(5)	(7)	(9)	(9)	(12)	(16)	(21)	(21)	(21)	(30)
	Capex	0	—	0	0	0	0	0	0	0	0
	Free cash flow	(5)	(7)	(9)	(9)	(12)	(16)	(21)	(21)	(21)	(30)
Balance, $m
Balance, $m	Working capital	2	7	9	13	27	138	113	87	69	37
	Total debt	—	—	—	0	0	—	—	—	—	—
	Net debt	(3)	(7)	(10)	(13)	(40)	(136)	(111)	(89)	(71)	(41)
	Shareholders’ equity	3	7	9	13	27	138	118	91	71	39
Returns, %
Returns, %	ROA	(122.62)	(173.71)	(230.17)	(131.55)	(77.90)	(22.39)	(20.36)	(27.39)	(29.54)	(56.06)
	ROIC	(35,321.81)	0.00	0.00	(2,321.12)	0.00	(777.78)	(248.52)	(801.74)	(6,100.04)	0.00
	ROE	(186.26)	(213.05)	(342.46)	(182.33)	(114.42)	(25.11)	(21.10)	(28.80)	(31.39)	(62.74)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2015 · latest quarter Dec 2014 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IBO Impact Biomedical Inc.	$27.0M	0.2×	—	−57.14% (below 0%: shrinking)	n/m	+167.72% (above 0%: growing)	66.67%	(23,400.00%)	Compare
ATOS Atossa Therapeutics, Inc.	$26.4M	— (loss-making)	—	−94.28% (below 0%: shrinking)	n/m	−32.86% (below 0%: shrinking)	0.00%	0.00%
IGC IGC Pharma, Inc.	$26.3M	— (loss-making)	— (loss-making)	−19.70% (below 0%: shrinking)	n/m	−103.33% (below 0%: shrinking)	18.11%	(1,050.57%)	Compare
MCRB Seres Therapeutics, Inc.	$25.2M	— (loss-making)	— (loss-making)	+96.79% (above 0%: growing)	n/m	−66.15% (below 0%: shrinking)	100.00%	(2,890.35%)	Compare
ABVC ABVC BioPharma, Inc.	$24.9M	— (loss-making)	— (loss-making)	+66,233.33% (above 0%: growing)	n/m	+72.66% (above 0%: growing)	100.00%	0.00%	Compare
BYSI BeyondSpring Inc.	$23.9M	— (loss-making)	— (loss-making)	+87.78% (above 0%: growing)	n/m	+35.78% (above 0%: growing)	100.00%	0.00%	Compare
CYAD Celyad SA	$23.8M	— (loss-making)	— (loss-making)	—	n/m	+78.72% (above 0%: growing)	0.00%	0.00%	Compare
PLRZ Polyrizon Ltd.	$23.7M	—	—	—	—	−744.51% (below 0%: shrinking)	—	—	Compare
IMMP Prima BioMed Ltd	$23.7M	— (loss-making)	—	—	n/m	−589,653.13% (below 0%: shrinking)	100.00%	(101.89%)	Compare
Median of peers	$24.4M	—	—	+87.78%	—	−15.18%	100.00%	(101.89%)

All 614 Biotechnology stocks →

Atossa Therapeutics, Inc. (ATOS) key facts

Atossa Therapeutics, Inc. (ATOS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ATOS traded at $2.91, a market capitalization of $26.4 million.
Return on equity was −62.7% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.